Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 9/20 | 0.73 |
| ▸ | GSK3A | P49840 | 2/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | FUT6 | P51993 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845832 | 0.95 | HINT1 (0.67) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL26622676 | 0.90 | HINT1 (0.62) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL26212718 | 0.87 | HINT1 (0.59) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL439016 | 0.87 | HINT1 (0.78) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL16163344 | 0.86 | HINT1 (0.70) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL26622675 | 0.86 | NT5E (0.61) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL1138984 | 0.86 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL2335177 | 0.86 | HINT1 (0.69) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL4963673 | 0.86 | HINT1 (0.60) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL6826563 | 0.85 | HINT1 (0.68) | HINT1GSK3ARPS6KA3MAPK14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12203072-B2 | Chemically modified single-stranded rna-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2025-01-21 | — | — | US | claimed |
| US-20240271131-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2024-08-15 | — | — | US | claimed |
| EP-4728071-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-04-22 | — | — | EP | disclosed |
| US-12398393-B2 | RNA-editing oligonucleotides for the treatment of usher syndrome | PROQR THERAPEUTICS II B.V. (NL) | 2025-08-26 | — | — | US | disclosed |
| US-12391929-B2 | Polymerase-nucleotide conjugates for sequencing by trapping | ELEMENT BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250236903-A1 | COMPOSITIONS AND METHODS FOR PAIRWISE SEQUENCING | ELEMENT BIOSCIENCES, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250223593-A1 | CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | PROQR THERAPEUTICS II B.V. (NL) | 2025-07-10 | — | — | US | disclosed |
| US-20250172547-A1 | MULTIVALENT BINDING COMPOSITION FOR NUCLEIC ACID ANALYSIS | ELEMENT BIOSCIENCES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250154504-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2025-05-15 | — | — | US | disclosed |
| US-12241891-B2 | Multivalent binding composition for nucleic acid analysis | ELEMENT BIOSCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4508060-A1 | RNA MOLECULE CONTAINING MODIFIED CAP ANALOGS AT THE 5 ' END, USE OF RNA MOLECULE IN IN VITRO PROTEIN OR PEPTIDE SYNTHESIS, RNA MOLECULE FOR USE IN MEDICINE, AND USE OF MODIFIED CAP ANALOGS FOR RNA CAPPING | Uniwersytet Warszawski (PL) | 2025-02-19 | — | — | EP | disclosed |
| WO-2012078559-A2 | SMALL-MOLECULE HYDROPHOBIC TAGGING OF FUSION PROTEINS AND INDUCED DEGRADATION OF SAME | YALE UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011028507-A2 | COMPOSITIONS, METHODS, AND KITS FOR DETERMINING AN ALKYL TRANSFERASE | DUKE UNIVERSITY (US) | 2011-03-10 | — | — | WO | disclosed |
| US-7385051-B2 | Fluorescent N2,N3-etheno-purine (2′-deoxy) riboside derivatives and uses thereof | BAR-LLAN UNIVERSITY (IL) | 2008-06-10 | — | — | US | disclosed |
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2006-07-27 | — | — | US | disclosed |
| WO-2001085221-A2 | ASSESSING LEVELS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE IN VIVO | DUKE UNIVERSITY (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-0523100-B1 | O6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | US HEALTH (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0523100-A4 | O?6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O?6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | US HEALTH (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0523100-A1 | O?6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O?6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY. | US HEALTH (US) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991013898-A1 | O6-BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154504-A1 | GUIDE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING IN THE TREATMENT OF HYPERCHOLESTEROLEMIA | PCSK9, LDLR, PCSK7 | HINT1 2038/4885GSK3A 708/4885RPS6KA3 2765/4885 |
| US-20060166248-A1 | Fluorescent N2, N3-etheno-purine (2'deoxy) riboside derivatives and uses thereof | NUDT1, NT5C2, DUT | HINT1 101/4885GSK3A 4807/4885RPS6KA3 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.